57-71-6 Usage
Chemical Properties
white crystals
Uses
2,3-Butanedione monoxime is a reversible inhibitor of myosin ATPase. It is also used as a reagent for colorimetric determination of urea.
Preparation
Approximately 9 moles of ethyl nitrite are required for this preparation. The literature indicates a suitable apparatus for its generation.
In a well-ventilated hood, to freshly dried and distilled methyl ethyl ketone (620 gm, 8.6 moles) is added, with stirring, 40 ml of cone, hydro-chloric acid. The temperature of the reaction system is raised to 40°C. Without delay the addition of ethyl nitrite is initiated and the flow of the reagent is regulated to such a rate that the reaction temperature never exceeds 55°C. About 1.5 hr are required for the addition. The ethanol formed in the reaction, as well as unreacted methyl ethyl ketone, is separated by distillation until the pot temperature just reaches 90°C.
The product is separated from the residue by rapid steam distillation. Virtually all of the product will be found in the first 5 liters of the distillate. The distillate is saturated with 1.5 kg of sodium chloride and cooled to 0°C. The product, which precipitates out, is filtered off. If necessary, the pro-duct may be recrystallized from water to afford 500 gm (58%), m.p. 76.5°C.
Air & Water Reactions
Soluble in water.
Reactivity Profile
2,3-Butanedione monoxime may react violently during vacuum distillation above 130 pascals.
Fire Hazard
Flash point data for 2,3-Butanedione monoxime are not available, but 2,3-Butanedione monoxime is probably combustible.
Biological Activity
2,3-butanedione-2-monoxime is a myosin atpase inhibitor.myosin, an atpase, can convert chemical energy into directed movement and is regarded as a molecular motor. myosin has various shapes and sizes. more than 11 myosin classes have been identified, and more will be found. the common feature of all of these molecules is a section close to the n terminus, which can be identified as a motor domain.
Biochem/physiol Actions
DRK1 is a delayed rectifier (Kv2.1) cloned K+ channel from rat brain with consensus sites for protein kinase-dependent phosphorylation that might be expected to be functionally regulated by phosphorylation. 2,3-Butanedione monoxime (BDM) chemically removes phosphate groups from many proteins, and its action on DRK1 channels was examined after expression of DRK1 cRNA in Xenopus oocytes. In two-microelectrode voltage-clamp experiments, the application of 2,3-Butanedione monoxime to the bath inhibited DRK1 current (ki = 16.6 mM, H = 0.96) rapidly and reversibly, with a time course similar to the time course of solution change within the bath. DRK1 current was inhibited at all potentials; the time course of current activation, deactivation and inactivation were unaffected by 2,3-Butanedione monoxime. In inside-out patch-clamp experiments, the application of 2,3-Butanedione monoxime to the cytoplasmic surface similarly inhibited channel activity rapidly and reversibly (ki = 10.7 mM, H = 1.01) in the absence of rephosphorylating substrates. These results are inconsistent with a phosphatase effect, because such an effect should be irreversible in cell-free, ATP-free patches. Instead, the results suggest that 2,3-Butanedione monoxime can inhibit DRK1 channels directly from inside or outside of the membrane.
in vitro
2,3-butanedione-2-monoxime (bdm), a general probe of myosin function, was widely used in muscle research as a low-affinity but specific chemical phosphatase that could reversibly inhibit the myosin cross-bridge cycle. it was found that wild-type cells treated with bdm at 20 mm for around two generation times were smaller than untreated controls and showed a septation index about twice that observed in the absence of the inhibitor. moreover, the organization of actin at the cell poles was disorganized in the presence of bdm, however, cells formed a cytokinetic actin ring. in addition, when nitrogen-starved stationary-phase cells were reinoculated into fresh medium in the presence of bdm, the time taken to repolarize the actin cytoskeleton and to resume the characteristic vegetative cell shape were both delayed substantially [1].
references
[1] may km, wheatley sp, amin v, hyams js. the myosin atpase inhibitor 2,3-butanedione-2-monoxime (bdm) inhibits tip growth and cytokinesis in the fission yeast, schizosaccharomyces pombe. cell motil cytoskeleton. 1998;41(2):117-25.
Check Digit Verification of cas no
The CAS Registry Mumber 57-71-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 7 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 57-71:
(4*5)+(3*7)+(2*7)+(1*1)=56
56 % 10 = 6
So 57-71-6 is a valid CAS Registry Number.
InChI:InChI=1/C4H7NO2/c1-3(5-7)4(2)6/h7H,1-2H3/b5-3+
57-71-6Relevant articles and documents
Visible-Light-Induced Transition-Metal-Free Nitrogen-Centered Radical Strategy for the Synthesis of 2-Acylated 9 H-Pyrrolo[1,2- a]indoles
Yu, Wen-Qin,Xie, Jun,Chen, Zan,Xiong, Bi-Quan,Liu, Yu,Tang, Ke-Wen
, p. 13720 - 13733 (2021/10/01)
A convenient and efficient visible-light-induced tandem acylation/cyclization of N-propargylindoles with aryl- or alkyl-substituted acyl oxime esters for the synthesis of 2-acyl-substituted 9H-pyrrolo[1,2-a]indoles under transition-metal-free conditions, which proceeds via nitrogen-centered radical-mediated cleavage of the C-C σ-bond in acyl oxime esters, is established. The aryl or alkyl acyl radicals, which come from acyl oxime esters, attack the C-C triple bonds in N-propargylindoles and then go through intramolecular cyclization/isomerization.
ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES
-
, (2008/06/13)
The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with arylcycloalkyl-substituted alkanoic acid derivatives and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of the formula I wherein the various substituent R-groups are more specifically defined herein.
Nitrosation of ketone dianions
Ikeda,Haraguchi,Yukawa,Niiya,Goto
, p. 526 - 528 (2007/10/02)
Nitrosation of α,α'-dianions produced from ketones using a couple of bases was carried out with tert-butyl nitrite(tert-BuONO) in ether, and then two regioisomers of oximes(but notacetone)were obtained simultaneously. The ratio of these regioisomers was remarkably reversed by the addition of hexamethylphosphoric triamide (HMPA).
